{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T08:28:42Z","timestamp":1787128122055,"version":"build-2736575974"},"reference-count":82,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Isocitrate Dehydrogenase (IDH)1\/2-mutant diffuse gliomas represent a biologically distinct subgroup of adult brain tumors in which eary metabolic reprogramming and accumulation of the oncometabolite D-2-hydroxyglutarate (D-2HG) drive epigenetic, immunologic, and clinical characteristics, including a high burden of glioma-associated epilepsy. This review summarizes the molecular and metabolic consequences of IDH mutations, their role in glioma-associated epilepsy, and the evolving impact of mutant IDH-targeted therapies in contemporary neuro-oncology. Methods: We conducted a narrative review of key molecular, translational, imaging, and clinical studies on IDH-mutant diffuse gliomas. The literature included the 2021 (World Health Organization) WHO Classification of Tumours of the Central Nervous System, studies investigating D-2HG biology and glioma-associated epilepsy, and prospective clinical trials and real-world evidence evaluating IDH-targeted therapies and contemporary antiseizure management. Particular emphasis was placed on vorasidenib, advanced metabolic imaging, and emerging liquid biopsy approaches. Results: IDH mutations are early driver events that promote D-2HG accumulation, resulting in widespread epigenetic reprogramming, metabolic dysregulation, and an immunosuppressive tumor microenvironment. D-2HG has also been implicated in the development of glioma-associated epilepsy, although the underlying mechanisms remain incompletely understood. Advances in integrated histomolecular diagnostics, magnetic resonance spectroscopy, amino acid positron emission tomography, and cerebrospinal fluid liquid biopsy have improved disease classification and treatment monitoring. Mutant IDH inhibitors, particularly vorasidenib, prolong progression-free survival, delay the need for subsequent treatment, and reduce intratumoral D-2HG concentrations, and have shown encouraging early signals of improved seizure control and preserved health-related quality of life in patients with grade 2 IDH-mutant gliomas, although this evidence remains preliminary and requires confirmation in larger prospective studies. Conclusions: IDH-mutant diffuse gliomas exemplify precision neuro-oncology, in which a single metabolic alteration informs diagnosis, disease monitoring, and targeted therapeutic approach. Additionally, ongoing studies are expected to further define the role of IDH inhibition across different disease stages and in combination with immunotherapy and standard treatments. Lastly, future clinical trials should systematically incorporate seizure outcomes, neurocognitive function, patient-reported outcomes, and immunologic endpoints to optimize both tumor control and quality of life.<\/jats:p>","DOI":"10.3390\/jcm15166387","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:12:11Z","timestamp":1787069531000},"page":"6387","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IDH-Mutant Diffuse Glioma: From Metabolic Origins to Targeted Therapy"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5101-868X","authenticated-orcid":false,"given":"Tadeja","family":"Urbanic-Purkart","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical University of Graz, Auenbruggerplatz 22, 8036 Graz, Austria"},{"name":"Division of Neuroradiology, Vascular and Interventional Radiology, Medical University of Graz, Auenbruggerplatz 22, 8036 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-024-00516-y","article-title":"Glioma","volume":"10","author":"Weller","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1470-2045(10)70053-X","article-title":"Isocitrate dehydrogenase-1 mutations: A fundamentally new understanding of diffuse glioma?","volume":"12","author":"Kloosterhof","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00401-009-0595-z","article-title":"Monoclonal antibody specific for IDH1 R132H mutation","volume":"118","author":"Capper","year":"2009","journal-title":"Acta Neuropathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1172\/JCI67229","article-title":"Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate","volume":"123","author":"Andronesi","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1078-0432.CCR-13-1333","article-title":"Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer","volume":"22","author":"Clark","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11060-025-05068-z","article-title":"Epidemiology of WHO grade 2 and grade 3 gliomas from 2009 to 2021 in Germany","volume":"174","author":"Weidl","year":"2025","journal-title":"J. Neurooncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ccr.2010.03.017","article-title":"Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma","volume":"17","author":"Noushmehr","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nature10866","article-title":"IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype","volume":"483","author":"Turcan","year":"2012","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2353\/ajpath.2009.080958","article-title":"IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas","volume":"174","author":"Watanabe","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/neuonc\/noac207","article-title":"Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions","volume":"25","author":"Miller","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2304194","article-title":"Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma","volume":"389","author":"Mellinghoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S1470-2045(25)00472-3","article-title":"Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): Secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"26","author":"Cloughesy","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41591-022-02141-2","article-title":"Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: A randomized, perioperative phase 1 trial","volume":"29","author":"Mellinghoff","year":"2023","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1038\/s41591-025-03884-4","article-title":"Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: A pilot trial","volume":"31","author":"Drummond","year":"2025","journal-title":"Nat. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/neuonc\/nou087","article-title":"The epidemiology of glioma in adults: A state of the science review","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/neuonc\/nov136","article-title":"Isocitrate dehydrogenase mutations in gliomas","volume":"18","author":"Waitkus","year":"2016","journal-title":"Neuro Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"eadt0559","DOI":"10.1126\/science.adt0559","article-title":"IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation","volume":"391","author":"Park","year":"2026","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1407279","article-title":"Glioma Groups Based on 1p\/19q, IDH, and TERT Promoter Mutations in Tumors","volume":"372","author":"Lachance","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network, Brat, D.J., Verhaak, R.G., Aldape, K.D., Yung, W.K., Salama, S.R., Cooper, L.A., Rheinbay, E., Miller, C.R., and Vitucci, M. (2015). Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N. Engl. J. Med., 372, 2481\u20132498.","DOI":"10.1056\/NEJMoa1402121"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature26000","article-title":"DNA methylation-based classification of central nervous system tumours","volume":"555","author":"Capper","year":"2018","journal-title":"Nature"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaf194","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2018-2022","volume":"27","author":"Price","year":"2025","journal-title":"Neuro Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s43018-025-01023-z","article-title":"Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling","volume":"6","author":"Vallentgoed","year":"2025","journal-title":"Nat. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/s41586-026-10612-6","article-title":"Acquired genetic and cell-state changes in IDH-mutant glioma progression","volume":"655","author":"Johnson","year":"2026","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/s41588-026-02642-7","article-title":"Longitudinal changes in DNA methylation in IDH-mutant glioma fuel disease progression through altered cell state differentiation","volume":"58","author":"Nomura","year":"2026","journal-title":"Nat. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Brat, D.J., Aldape, K., French, P.J., Louis, D.N., Nasrallah, M.P., Reifenberger, G., E Reuss, D., Touat, M., Bent, M.J.v.D., and Wesseling, P. (2026). cIMPACT-NOW update 12: Refining Pathology-based Risk Stratification and Grading for IDH-mutant Gliomas. Neuro Oncol., noag108.","DOI":"10.1093\/neuonc\/noag108"},{"key":"ref_30","first-page":"vdac097","article-title":"Prognostic impact of PDGFRA gain\/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma","volume":"4","author":"Higa","year":"2022","journal-title":"Neurooncol. Adv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ccell.2025.02.018","article-title":"Effective targeting of PDGFRA-altered high-grade glioma with avapritinib","volume":"43","author":"Mayr","year":"2025","journal-title":"Cancer Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41582-024-00967-7","article-title":"IDH inhibition in gliomas: From preclinical models to clinical trials","volume":"20","author":"Horbinski","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.15252\/emmm.201707729","article-title":"Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways","volume":"9","author":"Fack","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1038\/s41591-018-0095-6","article-title":"Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate","volume":"24","author":"Bunse","year":"2018","journal-title":"Nat. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.cell.2022.04.038","article-title":"Glioma progression is shaped by genetic evolution and microenvironment interactions","volume":"185","author":"Varn","year":"2022","journal-title":"Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1212\/WNL.0000000000003911","article-title":"Mutant IDH1 and seizures in patients with glioma","volume":"88","author":"Chen","year":"2017","journal-title":"Neurology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/WCO.0000000000001214","article-title":"Epilepsy in gliomas: Recent insights into risk factors and molecular pathways","volume":"36","author":"Bruno","year":"2023","journal-title":"Curr. Opin. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"McAfee, D., Moyer, M., Queen, J., Mortazavi, A., Boddeti, U., Bachani, M., Zaghloul, K., and Ksendzovsky, A. (2023). Differential metabolic alterations in IDH1 mutant vs. wildtype glioma cells promote epileptogenesis through distinctive mechanisms. Front. Cell. Neurosci., 17.","DOI":"10.3389\/fncel.2023.1288918"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"v218","DOI":"10.1093\/neuonc\/noad179.0835","article-title":"NCOG-22. Seizure outcome across disease trajectory in IDH-mutant grade 2 gliomas: Which is the impact of standard antineoplastic treatments?","volume":"25","author":"Bruno","year":"2023","journal-title":"Neuro Oncol."},{"key":"ref_41","first-page":"501","article-title":"Efficacy of antiepileptic drugs in glioma patients with epilepsy: A systematic review","volume":"8","author":"Dirven","year":"2021","journal-title":"Neurooncol. Pract."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Coppola, A., Zarabla, A., Maialetti, A., Villani, V., Koudriavtseva, T., Russo, E., Nozzolillo, A., Sueri, C., Belcastro, V., and Balestrini, S. (2020). Perampanel Confirms to Be Effective and Well-Tolerated as an Add-On Treatment in Patients with Brain Tumor-Related Epilepsy (PERADET Study). Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.00592"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/neuonc\/nov032","article-title":"Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: A systematic review","volume":"17","author":"Koekkoek","year":"2015","journal-title":"Neuro Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e168035","DOI":"10.1172\/JCI168035","article-title":"Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors","volume":"133","author":"Drumm","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_45","first-page":"e242","article-title":"Early seizure freedom with [18F]fluorodopa positron emission tomography response after isocitrate dehydrogenase inhibition with vorasidenib: First case report","volume":"66","author":"Bruno","year":"2025","journal-title":"Epilepsia"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Wick, W., Mellinghoff, I.K., Bent, M.J.v.D., Blumenthal, D.T., Touat, M., Peters, K.B., Clarke, J.L., Mendez, J.S., Welsh, L., and Mason, W.P. (2026). Impact of vorasidenib vs placebo on seizure rates and quality of life: Exploratory analysis from the phase 3 INDIGO study. J. Clin. Oncol., 44.","DOI":"10.1200\/JCO.2026.44.16_suppl.2043"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/neuonc\/noae213","article-title":"Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-Update 1","volume":"27","author":"Bent","year":"2025","journal-title":"Neuro Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"547","DOI":"10.5858\/arpa.2021-0295-CP","article-title":"Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas","volume":"146","author":"Brat","year":"2022","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_49","first-page":"e94","article-title":"In Vivo 2-Hydroxyglutarate Monitoring with Edited MR Spectroscopy for the Follow-up of IDH-Mutant Diffuse Gliomas: The IDASPE Prospective Study","volume":"100","author":"Nichelli","year":"2023","journal-title":"Neurology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/s41467-018-03905-6","article-title":"Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate","volume":"9","author":"Andronesi","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1158\/1078-0432.CCR-15-0656","article-title":"Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate","volume":"22","author":"Andronesi","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1158\/1078-0432.CCR-25-4313","article-title":"Ivosidenib and Vorasidenib decrease intratumoral 2-hydroxyglutarate and total choline levels in patients with lower-grade glioma: An in vivo MR Spectroscopy study","volume":"32","author":"Simicic","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_53","first-page":"vdac124","article-title":"Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas","volume":"4","author":"Cho","year":"2022","journal-title":"Neurooncol. Adv."},{"key":"ref_54","first-page":"vdae227","article-title":"Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomes","volume":"7","author":"Lanman","year":"2024","journal-title":"Neurooncol. Adv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","volume":"41","author":"Wen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1007\/s00259-026-07760-2","article-title":"Characteristics of [18F]FET PET and MRI in isocitrate dehydrogenase (IDH)-mutant gliomas diagnosed according to the WHO 2021 classification\u2014A retrospective analysis","volume":"53","author":"Barci","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_57","first-page":"vdae210","article-title":"Evaluation of early metabolic changes following vorasidenib using FET PET in patients with IDH-mutant gliomas","volume":"6","author":"Galldiks","year":"2024","journal-title":"Neurooncol. Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nm.2682","article-title":"2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas","volume":"18","author":"Choi","year":"2012","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41586-019-0882-3","article-title":"Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid","volume":"565","author":"Miller","year":"2019","journal-title":"Nature"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11912-024-01517-6","article-title":"Cerebrospinal Fluid Liquid Biopsies in the Evaluation of Adult Gliomas","volume":"26","author":"Valerius","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/neuonc\/noac004","article-title":"Liquid biopsy in gliomas: A RANO review and proposals for clinical applications","volume":"24","author":"Soffietti","year":"2022","journal-title":"Neuro Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1093\/neuonc\/noaf140","article-title":"Preanalytical variables and analytes in liquid biopsy approach for brain tumors: A comprehensive review and recommendations from the RANO Group and the Brain Liquid Biopsy Consortium","volume":"27","author":"Bettegowda","year":"2025","journal-title":"Neuro Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Crucitta, S., Pasqualetti, F., Gonnelli, A., Ruglioni, M., Luculli, G.I., Cantarella, M., Ortenzi, V., Scatena, C., Paiar, F., and Naccarato, A.G. (2024). IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients. BMC Cancer, 24.","DOI":"10.1186\/s12885-023-11726-0"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11910-024-01378-3","article-title":"The Role of Mutant IDH Inhibitors in the Treatment of Glioma","volume":"24","author":"Nakhate","year":"2024","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11864-026-01401-4","article-title":"Current Treatment Options for Adult Grade 2 IDH-mutant Diffuse Gliomas in the Vorasidenib Era: Patient Selection, Sequencing, and Practical Management","volume":"27","author":"Wu","year":"2026","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_67","first-page":"i2","article-title":"Practical management of patients with IDH-mutant glioma in the coming era of mIDH inhibitors: New drugs, new evidence, new guidelines, and new considerations","volume":"12","author":"Peters","year":"2024","journal-title":"Neurooncol. Pract."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Perazzoli, G., Prados, J., Ortiz, R., Caba, O., Cabeza, L., Berdasco, M., G\u00f3nzalez, B., and Melguizo, C. (2015). Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140131"},{"key":"ref_69","unstructured":"ClinicalTrials.gov (2026, August 01). A Phase 1b\/2, Multicenter Study of Vorasidenib in Combination with Temozolomide (TMZ) in Participants With IDH1- or IDH2-mutant Glioma. NCT06478212, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06478212."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Esparragosa V\u00e1zquez, I., de la Torre, I.F., Hilario, A., Lozano, I.I., Hern\u00e1ndez-La\u00edn, A., Pineda, E., S\u00e1nchez, J.M.S., and Vaz-Salgado, M.A. (2026). Multidisciplinary consensus recommendations for the management of IDH-mutant grade 2 gliomas in Spain: A Delphi study. Clin. Transl. Oncol.","DOI":"10.1007\/s12094-026-04338-0"},{"key":"ref_71","unstructured":"ClinicalTrials.gov (2026, August 01). Vorasidenib as Maintenance Treatment After First-Line Chemoradiotherapy in IDH-Mutant Grade 2 or 3 Astrocytoma: A Placebo-Controlled, Triple-Blind, Randomized Phase III Study (VIGOR). NCT06809322, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06809322."},{"key":"ref_72","unstructured":"ClinicalTrials.gov (2026, August 01). Phase III Trial of Radiotherapy Followed by Adjuvant Temozolomide in Combination with the IDH Inhibitor Vorasidenib vs. Placebo in IDH-Mutated Newly-Diagnosed Grade 3 Astrocytomas. NCT07215910, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07215910."},{"key":"ref_73","unstructured":"(2026, August 01). IDHEAL4U: International Phase 2\/3 Trial of Vorasidenib in Grade 4 IDH-Mutant Astrocytoma. CTIS 2024-513738-39-00. (NCT06478212; EU Trial [CTIS] No. 2024-513738-39-00; Protocol S095032-211). Available online: https:\/\/euclinicaltrials.eu\/ctis-public\/view\/2024-513738-39-00."},{"key":"ref_74","unstructured":"ClinicalTrials.gov (2026, August 01). Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma (VorPembro; NCT05484622), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05484622."},{"key":"ref_75","unstructured":"ClinicalTrials.gov (2026, August 01). ViCToRy: Vorasidenib in Combination with Tumor-Specific Peptide Vaccine for Recurrent IDH1-Mutant Lower Grade Gliomas (NCT05609994), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05609994."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Bunse, L., Lindner, K., Wick, A., Freitag, A., Lanz, L.-M., Edelmann, D., Suwala, A., Breckwoldt, M.O., Harting, I., and Sahm, F. (2026). IDH1-mutant vaccine in newly diagnosed astrocytoma: Final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial. Nat. Cancer, 76.","DOI":"10.1038\/s43018-026-01227-x"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Bunse, L., Rupp, A.-K., Poschke, I., Bunse, T., Lindner, K., Wick, A., Blobner, J., Misch, M., Tabatabai, G., and Glas, M. (2022). AMPLIFY-NEOVAC: A randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas. Neurol. Res. Pract., 4.","DOI":"10.1186\/s42466-022-00184-x"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","journal-title":"Nature"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"111281","DOI":"10.1016\/j.jocn.2025.111281","article-title":"Unlocking therapeutic synergy: IDH inhibitors and immunotherapy combination in preclinical and clinical IDH mutant glioma models\u2014A systematic review","volume":"136","author":"Ramadas","year":"2025","journal-title":"J. Clin. Neurosci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"34158","DOI":"10.18632\/oncotarget.8926","article-title":"Hyaluronic acid-conjugated liposome nanoparticles for targeted delivery to CD44 overexpressing glioblastoma cells","volume":"7","author":"Hayward","year":"2016","journal-title":"Oncotarget"},{"key":"ref_81","unstructured":"ClinicalTrials.gov (2026, August 01). A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants with Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma. NCT05303519, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05303519."},{"key":"ref_82","unstructured":"ClinicalTrials.gov (2026, August 01). Olutasidenib With Temozolomide After Radiotherapy in Newly Diagnosed Pediatric and Young Adult Patients with Grade 3 or 4 IDH1-Mutant Gliomas. NCT06161974, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06161974."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6387\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T08:18:55Z","timestamp":1787127535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":82,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15166387"],"URL":"https:\/\/doi.org\/10.3390\/jcm15166387","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}